Log in
NASDAQ:IMRA

IMARA Stock Forecast, Price & News

$25.51
-3.49 (-12.03 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$24.30
Now: $25.51
$29.10
50-Day Range
$15.81
MA: $19.57
$29.00
52-Week Range
$13.40
Now: $25.51
$62.71
Volume29,903 shs
Average Volume60,278 shs
Market Capitalization$444.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMRA
CUSIPN/A
CIKN/A
Phone617-206-2020
Employees16

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$444.05 million
Next Earnings Date2/4/2021 (Estimated)
OptionableNot Optionable
$25.51
-3.49 (-12.03 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IMARA (NASDAQ:IMRA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of IMARA?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMARA in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMARA
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IMARA?

Wall Street analysts have given IMARA a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IMARA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IMARA's next earnings date?

IMARA is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for IMARA
.

How were IMARA's earnings last quarter?

IMARA Inc. (NASDAQ:IMRA) posted its earnings results on Thursday, November, 5th. The company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.83) by $0.11.
View IMARA's earnings history
.

What price target have analysts set for IMRA?

4 brokerages have issued 12-month price targets for IMARA's shares. Their forecasts range from $25.00 to $64.00. On average, they anticipate IMARA's stock price to reach $38.50 in the next year. This suggests a possible upside of 50.9% from the stock's current price.
View analysts' price targets for IMARA
.

Who are some of IMARA's key competitors?

What other stocks do shareholders of IMARA own?

Who are IMARA's key executives?

IMARA's management team includes the following people:
  • Dr. Rahul D. Ballal Ph.D., Pres, CEO & Director (Age 42, Pay $580.26k)
  • Mr. Michael P. Gray CPA, M.B.A., MBA, CPA, CFO & COO (Age 49, Pay $478.38k)
  • Mr. Frank Waligora, VP of Technical Operations
  • Mr. Stephen M. Migausky, Sr. VP of Legal & Gen. Counsel
  • Ms. Joelle Lufkin MPH, Sr. VP of Devel.

When did IMARA IPO?

(IMRA) raised $76 million in an IPO on Thursday, March 12th 2020. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink served as the underwriters for the IPO.

What is IMARA's stock symbol?

IMARA trades on the NASDAQ under the ticker symbol "IMRA."

Who are IMARA's major shareholders?

IMARA's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.96%), State Street Corp (0.37%), California Public Employees Retirement System (0.23%), Charles Schwab Investment Management Inc. (0.18%), SG Americas Securities LLC (0.04%) and JPMorgan Chase & Co. (0.02%). Company insiders that own IMARA stock include Barbara Dalton and Bioscience Plc Arix.
View institutional ownership trends for IMARA
.

Which institutional investors are selling IMARA stock?

IMRA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for IMARA
.

Which institutional investors are buying IMARA stock?

IMRA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, SG Americas Securities LLC, and California Public Employees Retirement System. Company insiders that have bought IMARA stock in the last two years include Barbara Dalton, and Bioscience Plc Arix.
View insider buying and selling activity for IMARA
.

How do I buy shares of IMARA?

Shares of IMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMARA's stock price today?

One share of IMRA stock can currently be purchased for approximately $25.51.

How big of a company is IMARA?

IMARA has a market capitalization of $444.05 million. IMARA employs 16 workers across the globe.

What is IMARA's official website?

The official website for IMARA is www.imaratx.com.

How can I contact IMARA?

IMARA's mailing address is 116 HUNTINGTON AVENUE. 6TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 617-206-2020 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.